Alnylam Pharmaceuticals, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2008 | $65.5M | $54.7M | $10.8M | $18.0M |
| FY2009 | $-72.1M | $-77.1M | $4.9M | $19.7M |
| FY2010 | $-84.3M | $-89.1M | $4.7M | $19.1M |
| FY2011 | $-87.1M | $-88.4M | $1.3M | $16.7M |
| FY2012 | $-115.6M | $-124.0M | $8.3M | $12.4M |
| FY2013 | $-68.7M | $-72.7M | $4.0M | $20.7M |
| FY2014 | $-165.6M | $-174.6M | $9.0M | $33.1M |
| FY2015 | $-189.1M | $-202.1M | $13.0M | $45.8M |
| FY2016 | $-307.7M | $-372.3M | $64.6M | $75.5M |
| FY2017 | $-382.8M | $-487.0M | $104.2M | $92.8M |
| FY2018 | $-562.6M | $-689.5M | $126.9M | $157.8M |
| FY2019 | $-278.4M | $-418.6M | $140.2M | $174.8M |
| FY2020 | $-615.0M | $-685.3M | $70.4M | $139.9M |
| FY2021 | $-641.7M | $-718.1M | $76.4M | $165.7M |
| FY2022 | $-541.3M | $-613.3M | $72.1M | $230.6M |
| FY2023 | $104.2M | $41.9M | $62.2M | $221.7M |
| FY2024 | $-8.3M | $-42.6M | $34.3M | $272.1M |
| FY2025 | $524.1M | $465.4M | $58.7M | $348.2M |